Long-term care of pediatric renal transplant patients: From bench to bedside

Current Opinion in Pediatrics

Volumn 14, Issue 2, 2002, Pages 205-210

  Samsonov, Dmitry ^a   Briscoe, David M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; FAS LIGAND; GRANZYME B; HUMAN GROWTH HORMONE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PERFORIN; RAPAMYCIN; STEROID; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

BODY GROWTH; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE MARKER; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GROWTH RETARDATION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW;

CALCINEURIN; CHILD; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMAN GROWTH HORMONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RECEPTORS, INTERLEUKIN-2; RISK FACTORS; SIROLIMUS;

EID: 0036117842     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200204000-00010     Document Type: Review

References (41)

1. Subclinical rejection: A potential surrogate marker for chronic rejection may be diagnosed by protocol biopsy or urine spectroscopy
2. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine
3. Adjusting immunosuppression to the identification of T-cell activating mediators in rejecting transplants: A novel approach to rejection diagnosis and treatment
4. Glomerular hypertension: An under-appreciated aspect of chronic rejection
5. The hyperfiltration hypothesis in human renal transplantation
6. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant
7. Prospects and applicability of molecular diagnosis of allograft rejection
8. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection
9. The role of the graft endothelium in transplant rejection: Evidence that endothelial activation may serve as a clinical marker for the development of chronic rejection
10. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: Implications for the pathogenesis of chronic allograft nephropathy
11. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy
12. Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipients
13. The impact of acute rejection on chronic rejection: A report of the North American Pediatric Renal Transplant Cooperative Study
14. Improved graft survival after renal transplantation in the United States, 1988 to 1996
15. CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury
16. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure
17. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide
18. The 12th Annual Report of the North American Pediatric Renal Transplant Cooperative Study: Renal transplantation from 1987 through 1998
19. Nonimmune risk factors for chronic allograft disfunction
20. Nonimmunologic predictors of chronic renal allograft failure: Data from the United Network of Organ Sharing
21. Chronic allograft nephropathy: Prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution
22. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy
23. Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy
24. Mig, IP-10, and CXCR3 gene expression is predictive for the individual response of children with chronic allograft nephropathy to mycophenolate mofetil
25. Human allograft acceptance is associated with immune regulation
26. Cyclosporin A (Neoral) in pediatric organ transplantation
27. Immunosuppressive strategies in transplantation
28. Immunologic targets for currently available immunosuppressive agents: What is the optimal approach for children?
29. Tacrolimus: The good, the bad, and the ugly
30. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression
31. Rapamycin in transplantation: A review of the evidence
32. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
33. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
34. Promising early outcomes with a novel, complete steroid avoidance immunosuppress on protocol in pediatric renal transplantation
35. The impact of recombinant human growth hormone treatment on final adult height
36. Unique aspects of chronic rejection in pediatric renal transplants recipients
37. Challenges after pediatric transplantation
38. Growth and renal function after steroid-free tacrolimus-based immunosuppression in children with renal transplants
39. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)
40. Post-transplant lymphoproliferative disease in children